Zacho Helle D, Manresa José A B, Mortensen Jesper C, Bertelsen Henrik, Petersen Lars J
aDepartement of Nuclear Medicine, Clinical Cancer Research Center, Aalborg University Hospital bDepartment of Health Science and Technology cDepartment of Clinical Medicine, Aalborg University, Aalborg dDepartment of Clinical Physiology, Viborg Hospital, Viborg eDepartment of Nuclear Medicine, Regional Hospital West Jutland, Jutland fDepartment of Clinical Physiology and Nuclear Medicine, Randers Hospital, Randers, Denmark.
Nucl Med Commun. 2015 May;36(5):445-51. doi: 10.1097/MNM.0000000000000279.
The aim of the study was to assess the agreement in the interpretation of bone scintigraphy (BS) in a newly diagnosed prostate cancer.
A total of 635 consecutive patients had their planar whole-body BS independently reviewed by three nuclear medicine physicians and classified by two grading systems: (a) a four-category scale (1: benign; 2: equivocal; 3: most likely malignant; and 4: multiple metastases) and (b) a dichotomous scale (bone metastasis present or absent).
Agreement in the same category, or with one or two categories of differences, was found in 66, 34, and 1.3% of the readings, respectively. Average κ-values were 0.59, 0.72, and 0.83 for unweighted, linear, and quadratic weighted variants, respectively. Very high agreement was observed (96% of the readings) with the dichotomous scale (average κ=0.87); a comparison with a final imaging diagnosis with additional CT or MRI showed a sensitivity of 83% and a specificity of 98%. BS categories 1, 3, and 4 were consistent with the final imaging diagnosis in 96-99% of cases. The prevalence of metastasis was 10% in category 2. To optimize the diagnostic characteristics, category 2 should be regarded as a separate option.
Close agreement was found among trained observers for the evaluation of BS in prostate cancer. The high level of agreement with a dichotomous scale was hampered by diagnostic misclassification. A scale with equivocal findings on planar BS is considered important to allow for additional imaging and correct staging at the bone level of BS in a population with newly diagnosed prostate cancer.
本研究旨在评估新诊断前列腺癌患者骨闪烁显像(BS)解读的一致性。
共有635例连续患者的全身平面BS由三名核医学医师独立评估,并采用两种分级系统进行分类:(a)四类量表(1:良性;2:可疑;3:极有可能为恶性;4:多发转移)和(b)二分法量表(存在或不存在骨转移)。
分别在66%、34%和1.3%的读数中发现同一类别或相差一到两个类别的一致性。未加权、线性加权和二次加权变体的平均κ值分别为0.59、0.72和0.83。二分法量表观察到非常高的一致性(96%的读数)(平均κ=0.87);与最终成像诊断(额外的CT或MRI)比较显示敏感性为83%,特异性为98%。BS类别1、3和4在96 - 99%的病例中与最终成像诊断一致。类别2中转移的患病率为10%。为优化诊断特征,应将类别2视为一个单独的选项。
在前列腺癌BS评估方面,训练有素的观察者之间存在高度一致性。二分法量表的高度一致性受到诊断错误分类的影响。平面BS上存在可疑结果的量表对于在新诊断前列腺癌人群中进行额外成像以及在BS的骨水平进行正确分期很重要。